UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5748-5754

2008

Volltextzugriff (PDF)

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

Cancer, 2015-02, Vol.121 (3), p.432-440

2015

Volltextzugriff (PDF)

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2005-01, Vol.23 (1), p.133-141

2005

Volltextzugriff (PDF)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002535

2021

Volltextzugriff (PDF)

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Journal of clinical oncology, 2020-02, Vol.38 (6), p.567-575

2020

Volltextzugriff (PDF)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Journal for immunotherapy of cancer, 2018-07, Vol.6 (1), p.76-8, Article 76

2018

Volltextzugriff (PDF)

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group

Journal of clinical oncology, 2002-04, Vol.20 (8), p.2058-2066

2002

Volltextzugriff (PDF)

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome

Journal of clinical oncology, 2002-04, Vol.20 (8), p.2067-2075

2002

Volltextzugriff (PDF)

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3771-3778

2014

Volltextzugriff (PDF)

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer

Journal of clinical oncology, 2015-01, Vol.33 (1), p.58-64

2015

Volltextzugriff (PDF)

A Phase 2 Trial of Complete Resection for Stage IV Melanoma: Results of Southwest Oncology Group Clinical Trial S9430

Cancer, 2011-10, Vol.117 (20), p.4740-4746

2011

Volltextzugriff (PDF)

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer

Urology (Ridgewood, N.J.), 1998-08, Vol.52 (2), p.257-260

1998

Volltextzugriff (PDF)

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

Clinical cancer research, 2012-02, Vol.18 (4), p.1129-1137

2012

Volltextzugriff (PDF)

A phase 2 trial of complete resection for stage IV melanoma

Cancer, 2011-10, Vol.117 (20), p.4740-4746

2011

Volltextzugriff (PDF)

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

Journal of clinical oncology, 2000-06, Vol.18 (12), p.2444-2458

2000

Volltextzugriff (PDF)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma

Cancer medicine (Malden, MA), 2017-11, Vol.6 (11), p.2576-2585

2017

Volltextzugriff (PDF)

Targeted therapies: Improved outcomes for patients with metastatic melanoma

Nature reviews. Clinical oncology, 2011-09, Vol.8 (9), p.513

2011

Volltextzugriff (PDF)

New Options for the Adjuvant Treatment of Cutaneous Melanoma?

Current oncology reports, 2014-11, Vol.16 (11), p.409-409, Article 409

2014

Volltextzugriff (PDF)

A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331)

American journal of clinical oncology, 2010-10, Vol.33 (5), p.495-499

2010

Volltextzugriff (PDF)

Improved outcomes for patients with metastatic melanoma

Nature reviews. Clinical oncology, 2011-09, Vol.8 (9), p.513-515

2011

Volltextzugriff (PDF)

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

The Lancet (British edition), 2008-07, Vol.372 (9633), p.89-90

2008

Volltextzugriff (PDF)

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

Cancer, 2010-01, Vol.116 (2), p.424-431

2010

Volltextzugriff (PDF)

Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival

Cancer immunology research, 2014-10, Vol.2 (10), p.981-987

2014

Volltextzugriff (PDF)

Risk assessment in localized primary cutaneous melanoma: A southwest oncology group study evaluating nine factors and a test of the Clark logistic regression prediction model

American journal of clinical pathology, 2002-10, Vol.118 (4), p.504-511

2002

Volltextzugriff (PDF)

1 – 25 von 124

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(122)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(123)
Berichte
(1)

Sprache

Englisch
(124)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Humans
(78)
Life Sciences & Biomedicine
(78)
Oncology
(64)
Middle Aged
(53)
Female
(52)
Male
(52)
Aged
(45)
Biological And Medical Sciences
(45)
Medical Sciences
(45)
Melanoma - Drug Therapy
(45)
Adult
(40)
Antineoplastic Agents
(30)
Melanoma - Pathology
(28)
Pharmacology. Drug Treatments
(28)
Melanoma
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(24)
Aged, 80 And Over
(22)
Melanoma - Secondary
(21)
Chemotherapy
(18)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome

SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer

A Phase 2 Trial of Complete Resection for Stage IV Melanoma: Results of Southwest Oncology Group Clinical Trial S9430

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

A phase 2 trial of complete resection for stage IV melanoma

High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma

Targeted therapies: Improved outcomes for patients with metastatic melanoma

New Options for the Adjuvant Treatment of Cutaneous Melanoma?

A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331)

Improved outcomes for patients with metastatic melanoma

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508

Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival

Risk assessment in localized primary cutaneous melanoma: A southwest oncology group study evaluating nine factors and a test of the Clark logistic regression prediction model

Suchergebnisse filtern